僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Concizumab is an anti-TFPI monoclonal antibody （IgG4 type） that binds to the Kunitz-type protease inhibitor （KPI） 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia